|
|
 |
 |
|
|
| Antiplatelet drugs in the secondary prevention after stroke - differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2 |
|
23 January 2006
Arterial disease resulting in cerebral ischaemia can be classified into large vessel disease (LVD) and small vessel disease (SVD). Dr Ariesen and her group from the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, assessed whether antiplatelet drugs were more efficacious in large than in small vessel cerebrovascular disease.
Individual patient data of the second European Stroke Prevention Study (n=6602), in which patients with a previous transient ischaemic attack or ischaemic stroke were randomised to aspirin, dipyridamole, their combination, or placebo, were reanalysed. Type of vessel disease was classified according to clinical symptoms or physical examination. Presence of a lacunar syndrome was considered typical for SVD and evidence of cortical dysfunction for LVD. Vascular events (nonfatal stroke, nonfatal myocardial infarction, nonfatal other vascular event, or vascular death) were taken as outcome.
A total of 419 first vascular events occurred in 2600 patients with SVD and 367 in 1816 patients with LVD (mean follow-up 1.7 years). For aspirin versus placebo, the hazard ratio (HR) was 0.86 (95% CI, 0.66 to 1.11) in patients with SVD and 0.80 (95% CI, 0.61 to 1.06) in those with LVD (Pinteraction=0.74). For dipyridamole versus placebo, the HR was 0.86 (95% CI, 0.67 to 1.12) in patients with SVD and 0.90 (95% CI, 0.68 to 1.19) in patients with LVD (Pinteraction=0.84). Similar observations were made for the outcome stroke only.
The investigators concluded that the findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischaemia that was caused by LVD compared with SVD.
Reference:
Stroke 2006; 37 (1): 134-138.
 Back to selection |
|
 |
|
|
|
